Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines.
How has the overall situation for innovative pharmaceutical companies evolved over your time as head of the Association of the Research-Based Pharmaceutical Manufacturers (ARPharM) in Bulgaria?
"Bulgarian patients’ access to innovative medicines has drastically improved over the last decade"
